Laurus Labs Share Price - Live NSE: LAURUSLABS Stock Price & Chart
NiveshIQ
NSE: LAURUSLABS · Healthcare
Laurus Labs Ltd.
₹2,348.00▼ ₹57.50 (-2.39%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on LAURUSLABS. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Laurus Labs Ltd.
Laurus Labs Limited, headquartered in Hyderabad, specializes in manufacturing and selling generic APIs and solid oral drug products for a broad therapeutic portfolio that includes anti‑retroviral, anti‑diabetic, cardiovascular, anti‑asthma, ophthalmology, oncology, and gastroenterology indications. The company also offers animal‑origin‑free recombinant proteins, cell‑culture media supplements, and a full suite of CDMO services such as drug substance, drug product, and biologics development, positioning it as a one‑stop solution for both small‑molecule and biologic manufacturers. In Q2 FY27, Laurus Labs recorded revenue of ₹7,270 Cr and net income of ₹1,093 Cr, with an EBITDA margin of 34.5%, reflecting strong demand for its CDMO and complex‑modality capabilities. The firm has recently appr
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹5,041 Cr -16.55% | ₹5,554 Cr +10.18% | ₹6,813 Cr +22.67% |
| EBITDA Margin | 15.42% | 19.00% | 26.09% |
| Net Profit | ₹160.55 Cr -79.68% | ₹358.32 Cr +123.18% | ₹888.79 Cr +148.04% |
| EPS | ₹2.98 | ₹6.65 | ₹16.47 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Laurus Labs Shares Rise 5% After Q2 FY27 Net Profit Jumps 126%
Laurus Labs Q2 Profit Jumps 126% to ₹441 Crore; EBITDA Rises 78%
🔒
+ 3 more stories about Laurus Labs Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q2FY27 results: revenue ₹2, 206 Cr, PAT ₹441 Cr, EPS ₹8.17, EBITDA margin 34.0%. Growth context: revenue YoY +33.4%, PAT YoY +126.4%, revenue QoQ +8.9%, PAT QoQ +20.1%.
Management commentary points to new capacity addition and capex deployment as the primary near-term growth lever, with e...
FY26 (last completed FY): revenue ₹6, 813 Cr, PAT ₹889 Cr, EBITDA margin 26.1%, EPS ₹16.47. Year-on-year: revenue YoY +2...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for LAURUSLABS
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track LAURUSLABS alongside your other holdings
Unlock full LAURUSLABS research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Laurus Labs Ltd.?
NiveshIQ detects active intelligence signals for Laurus Labs Ltd. (LAURUSLABS) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Laurus Labs Ltd.?
Laurus Labs Ltd. operates in the Healthcare sector with a market capitalisation of ₹10,346,978.3L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.